Publication date: Oct 15, 2024
To examine the impact of the COVID-19 pandemic on deprivation-related inequalities in hospitalisations for cardiovascular disease (CVD) conditions in Denmark and England between March 2018 and December 2021. Time-series studies in England and Denmark. With the approval of National Health Service England, we used English primary care electronic health records, linked to secondary care and death registry data through the OpenSAFELY platform and nationwide Danish health registry data. We included adults aged 18 and over without missing age, sex or deprivation information. On 1 March 2020, 16 234 700 people in England and 4 491 336 people in Denmark met the inclusion criteria. Hospital admissions with the primary reason for myocardial infarction (MI), ischaemic or haemorrhagic stroke, heart failure and venous thromboembolism (VTE). We saw deprivation gradients in monthly CVD hospitalisations in both countries, with differences more pronounced in Denmark. Based on pre-pandemic trends, in England, there were an estimated 2608 fewer admissions than expected for heart failure in the most deprived quintile during the pandemic compared with an estimated 979 fewer admissions in the least deprived quintile. For all other outcomes, there was little variation by deprivation quintile. In Denmark, there were an estimated 1013 fewer admissions than expected over the pandemic for MI in the most deprived quintile compared with 619 in the least deprived quintile. Similar trends were seen for stroke and VTE, though absolute numbers were smaller. Heart failure admissions were similar to pre-pandemic levels with little variation by deprivation quintile. Overall, we did not find that the pandemic substantially worsened pre-existing deprivation-related differences in CVD hospitalisations, though there were exceptions in both countries.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 pandemic |
disease | MESH | cardiovascular disease |
disease | MESH | death |
drug | DRUGBANK | Methionine |
disease | MESH | myocardial infarction |
disease | MESH | stroke |
disease | MESH | heart failure |
disease | MESH | venous thromboembolism |
drug | DRUGBANK | Coenzyme M |
disease | IDO | intervention |
disease | IDO | country |
disease | MESH | emergency |
disease | MESH | educational level |
disease | IDO | quality |
drug | DRUGBANK | Imidacloprid |
drug | DRUGBANK | Hexachlorophene |
disease | MESH | infarction |
disease | MESH | diabetes mellitus |
disease | MESH | asthma |
pathway | KEGG | Asthma |
disease | MESH | COPD |
drug | DRUGBANK | Trestolone |
drug | DRUGBANK | Flunarizine |
disease | MESH | acute coronary syndromes |
disease | MESH | thromboembolism |
drug | DRUGBANK | Ranitidine |
drug | DRUGBANK | Medical air |
disease | IDO | process |
pathway | REACTOME | Translation |
disease | MESH | premature mortality |
disease | MESH | infection |
disease | MESH | retirement |
disease | MESH | privacy |
drug | DRUGBANK | Huperzine B |
drug | DRUGBANK | Nonoxynol-9 |
disease | MESH | Acute Ischemic Stroke |